# Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

> **NCT00447187** · PHASE3 · TERMINATED · sponsor: **Lux Biosciences, Inc.** · enrollment: 368 (actual)

## Conditions studied

- Corneal Diseases
- Cornea Transplant

## Interventions

- **DRUG:** LX201
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00447187
- **Lead sponsor:** Lux Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2009-03
- **Final completion:** 2010-11
- **Target enrollment:** 368 (ACTUAL)
- **Why stopped:** The primary efficacy endpoint was not met
- **Last updated:** 2012-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447187, "Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00447187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*